March 28, 2018 08:38 AM EDT
R&D

Blue­bird whis­tles up a co-de­vel­op­ment/co-pro­mo­tion pact with Cel­gene on bb2121 CAR-T

John Carroll

Editor & Founder

Blue­bird bio $BLUE has picked up an op­tion to co-pro­mote and co-de­vel­op its close­ly-watched an­ti-BC­MA CAR-T bb2121 for mul­ti­ple myelo­ma pa­tients along­side Cel­gene $CELG. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

A service from the Financial Times